Naglazyme (Galsulfase)

Galsulfase, the active ingredient in Naglazyme, is an enzyme replacement therapy presented as a solution for injection for intravenous use. It treats mucopolysaccharidosis type VI (Maroteaux‑Lamy syndrome) in patients with the inherited enzyme deficiency.

GNH USA supplies Naglazyme as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Naglazyme is an enzyme replacement therapy indicated for a lysosomal storage disorder affecting glycosaminoglycan degradation.

- Mucopolysaccharidosis type VI (Maroteaux‑Lamy syndrome): Improves breakdown of accumulated dermatan sulfate and chondroitin‑4‑sulfate, helping to stabilize or improve clinical symptoms such as joint stiffness, organ enlargement, and respiratory function.

Common Side Effects: - Infusion‑related reactions (fever, chills, headache) - Nausea or vomiting - Mild rash or erythema at the infusion site - Transient abdominal discomfort - Fatigue or malaise

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Serum sickness‑like illness - Significant hepatic enzyme elevation - Thrombocytopenia or other hematologic abnormalities - Severe pulmonary or cardiac complications

Naglazyme requires individualized dosing and careful monitoring by a specialist.

- Dose individualization: dosing is based on body weight and clinical response as determined by the prescribing physician. - Monitoring: regular assessment of urinary glycosaminoglycan levels and organ function is recommended. - Allergy assessment: evaluate for hypersensitivity to galsulfase or any excipients before initiation. - Pregnancy and lactation: safety not established; use only if potential benefit justifies the risk. - Immunogenicity: antibodies may develop, potentially reducing efficacy or causing reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Naglazyme has a limited interaction profile, but caution is advised with certain co‑administered agents.

Major Interactions (Avoid): - Concurrent lysosomal enzymes: may increase risk of additive immune responses. - Live vaccines: potential for altered immune response; avoid simultaneous administration.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of infusion reactions. - Corticosteroids: can reduce antibody formation, potentially affecting efficacy. - Immunosuppressants: may alter the immune response to the enzyme and affect safety monitoring.